本文選題：特發(fā)性肺纖維化 + 血府逐瘀膠囊��； 參考：《中華中醫(yī)藥雜志》2015年02期

【摘要】：目的:觀察血府逐瘀膠囊聯(lián)合N-乙酰半胱氨酸抑制特發(fā)性肺纖維化(IPF)進展的有效性和安全性。方法:選擇臨床診斷IPF患者40例,隨機分為治療組(20例)和對照組(20例),兩組均予N-乙酰半胱氨酸口服,1片/次,2次/d,治療組聯(lián)合血府逐瘀膠囊口服,5粒/次,2次/d,均治療18個月,評價疾病無進展生存(PFS)率和時間、IPF急性加重(AE-IPF)發(fā)生率、肺功能(TLC、FVC、DLCO)、6MWT(距離、6MWT前/后Sp O2)、Borg評分與基線水平差值。結果:完成研究34例(治療組18例、對照組16例),治療組PFS率(77.8%)高于對照組(50.0%),治療組PFS時間(16.70個月)高于對照組(14.16個月),差異無統(tǒng)計學意義;治療組AEIPF發(fā)生率(5.6%)低于對照組(12.5%),差異無統(tǒng)計學意義;治療組TLC、FVC、DLCO降低值均低于對照組,差異無統(tǒng)計學意義,治療組6MWT距離、6MWT后Sp O2降低值均低于對照組,差異有統(tǒng)計學意義(P0.05),治療組6MWT前Sp O2降低值低于對照組,差異無統(tǒng)計學意義,治療組Borg評分降低值低于對照組,差異有統(tǒng)計學意義(P0.05)。治療組不良反應發(fā)生率(11.11%)高于對照組(6.25%),差異無統(tǒng)計學意義。結論:聯(lián)合治療有減少IPF疾病進展和急性加重次數(shù)的趨勢,可減緩肺功能和運動耐量下降速度。
[Abstract]:Aim: to observe the efficacy and safety of Xuefu Zhuyu capsule combined with N-acetylcysteine in inhibiting the progression of idiopathic pulmonary fibrosis (IPF). Methods: 40 patients with IPF were selected. Two groups were randomly divided into treatment group (n = 20) and control group (n = 20). Both groups were treated with N- acetylcysteine orally for 2 times a day, and the treatment group combined with Xuefu Zhuyu capsule for two times a day for 18 months. The PFSs rate and time of acute exacerbation of IPF were evaluated, and the difference between the baseline level and the lung function of TLCFV / DLCOC / 6MWTwas evaluated. Results: 34 cases (18 cases in the treatment group and 16 cases in the control group) completed the study. The PFS rate of the treatment group was 77.8% higher than that of the control group (50.0%). The PFS time of the treatment group (16.70 months) was higher than that of the control group (14.16 months), and the difference was not statistically significant. The incidence of AEIPF in the treatment group (5.6m) was lower than that in the control group (12.5MWT), the difference was not statistically significant (P < 0.05), the decrease value of AEIPF in the treatment group was lower than that in the control group (P < 0.01), and the decrease value of SPO _ 2 in the treatment group was lower than that in the control group after 6MWT distance was 6MWT. The difference was statistically significant (P 0.05). The decrease of SPO 2 before 6MWT in the treatment group was lower than that in the control group, but the difference was not statistically significant. The Borg score in the treatment group was lower than that in the control group, and the difference was statistically significant (P 0.05). The incidence of adverse reactions in treatment group (11.11) was higher than that in control group (6.25%). Conclusion: combined therapy has a tendency to reduce the progression and acute exacerbation of IPF, and can slow down the decline of pulmonary function and exercise tolerance.
【作者單位】： 天津中醫(yī)藥大學第一附屬醫(yī)院;
【分類號】：R563.9

【參考文獻】

相關期刊論文 前3條

1 譚曉麗;王真;;從瘀論治間質性肺疾病[J];長春中醫(yī)藥大學學報;2013年06期

2 王立娟;賈新華;張心月;;肺纖維化從瘀論治探析[J];天津中醫(yī)藥大學學報;2012年04期

3 王立娟;賈新華;張心月;陳憲海;張興彩;朱雪;張偉;;活血化瘀藥在肺間質纖維化治療中的應用[J];吉林中醫(yī)藥;2012年03期

【共引文獻】

相關期刊論文 前6條

1 楊秀玲;;益氣化痰活血法聯(lián)合西醫(yī)治療對肺間質纖維化的氧化應激反應與炎癥因子的影響研究[J];中醫(yī)藥導報;2014年12期

2 袁成波;王檀;仕麗;;應用清宣止咳除痹湯治療間質性肺疾病(脾經(jīng)伏火,肺絡痹阻癥)60例臨床觀察[J];中國繼續(xù)醫(yī)學教育;2015年01期

3 屈毓敏;王辛秋;王雪京;晁恩祥;;晁恩祥教授辨治特發(fā)性肺間質纖維化經(jīng)驗探析[J];天津中醫(yī)藥;2014年09期

4 林琳;許銀姬;吳蕾;陳芝喜;于旭華;;健脾益肺Ⅱ號對熏煙聯(lián)合脂多糖誘導大鼠炎癥因子及金屬蛋白酶表達的影響[J];天津中醫(yī)藥大學學報;2014年06期

5 袁成波;王檀;仕麗;;暖肝除痹湯治療間質性肺疾病肝腎陰寒證[J];吉林中醫(yī)藥;2013年12期

6 車麗;張偉;;血瘀對肺間質纖維化的影響[J];吉林中醫(yī)藥;2014年02期

相關碩士學位論文 前3條

1 余松;70例肺間質纖維化患者舌象的臨床觀察[D];北京中醫(yī)藥大學;2013年

2 胡旭;Th1/Th2細胞因子與特發(fā)性肺纖維化預后關聯(lián)性的研究[D];河北醫(yī)科大學;2013年

3 梁倩;恲肺飲及其拆方對急性肺損傷后肺纖維化大鼠模型Smad2/3表達影響研究[D];河北醫(yī)科大學;2014年

【二級參考文獻】

相關期刊論文 前10條

1 焦揚;周平安;;肺間質纖維化的病因病機和辨證論治述要[J];北京中醫(yī);2007年10期

2 付小芳;劉錫f，

本文編號：1795483